自付费用与常见神经科药物依从性的关联
该研究利用2001至2016年私人保险理赔数据,纳入新发周围神经病、痴呆或帕金森病患者,分析自付费用与药物依从性的关联。结果显示,自付费用每增加50美元,加巴喷丁类治疗的周围神经病患者和胆碱酯酶抑制剂治疗的痴呆患者依从性显著降低,而SNRI治疗的周围神经病患者和 dopamine agonist 治疗的帕金森病患者未达显著。少数族裔依从性更低。
要点
- 自付费用增加与加巴喷丁类及胆碱酯酶抑制剂依从性下降显著相关。
- SNRI和 dopamine agonist 治疗中该关联未达统计学显著。
- 少数族裔患者使用加巴喷丁类和胆碱酯酶抑制剂的依从性低于白人。
核心结论
- 在三种常见神经科疾病中,较高的自付费用与较低的药物依从性相关。
- 医生处方时应考虑费用以提高依从性,尤其费用持续上涨背景下。
- 少数族裔患者依从性更低,未来干预应重点关注。
研究设计与样本
- 基于2001至2016年私人保险理赔数据的回顾性队列研究。
- 纳入新发周围神经病、痴呆或帕金森病患者,处方疗效与耐受性相似但自付费用不同的药物。
- 样本包括52,249例使用加巴喷丁类的周围神经病患者、5,246例使用SNRI的周围神经病患者、19,820例使用胆碱酯酶抑制剂的痴呆患者和3,130例使用 dopamine agonist 的帕金森病患者。
- 采用工具变量分析估计自付费用与药物依从性的关联。
- 依从性定义为前6个月内供药天数。
主要发现
- 少数族裔患者使用加巴喷丁类和胆碱酯酶抑制剂的依从性低于白人患者。
临床怎么用
- 处方常见神经科药物时,医生应主动考虑患者自付费用以改善依从性。
- 对少数族裔患者应给予额外关注,以缩小依从性差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the association between out-of-pocket costs and medication adherence in 3 common neurologic diseases. METHODS: Utilizing privately insured claims from 2001 to 2016, we identified patients with incident neuropathy, dementia, or Parkinson disease (PD). We selected patients who were prescribed medications with similar efficacy and tolerability, but differential out-of-pocket costs (neuropathy with gabapentinoids or mixed serotonin/norepinephrine reuptake inhibitors [SNRIs], dementia with cholinesterase inhibitors, PD with dopamine agonists). Medication adherence was defined as the number of days supplied in the first 6 months. Instrumental variable analysis was used to estimate the association of out-of-pocket costs and other patient factors on medication adherence. RESULTS: We identified 52,249 patients with neuropathy on gabapentinoids, 5,246 patients with neuropathy on SNRIs, 19,820 patients with dementia on cholinesterase inhibitors, and 3,130 patients with PD on dopamine agonists. Increasing out-of-pocket costs by $50 was associated with significantly lower medication adherence for patients with neuropathy on gabapentinoids (adjusted incidence rate ratio [IRR] 0.91, 0.89-0.93) and dementia (adjusted IRR 0.88, 0.86-0.91). Increased out-of-pocket costs for patients with neuropathy on SNRIs (adjusted IRR 0.97, 0.88-1.08) and patients with PD (adjusted IRR 0.90, 0.81-1.00) were not significantly associated with medication adherence. Minority populations had lower adherence with gabapentinoids and cholinesterase inhibitors compared to white patients. CONCLUSIONS: Higher out-of-pocket costs were associated with lower medication adherence in 3 common neurologic conditions. When prescribing medications, physicians should consider these costs in order to increase adherence, especially as out-of-pocket costs continue to rise. Racial/ethnic disparities were also observed; therefore, minority populations should receive additional focus in future intervention efforts to improve adherence.
引用
- Reynolds EL, Burke JF, Banerjee M, et al. Association of out-of-pocket costs on adherence to common neurologic medications. Neurology. 2020. PMID: 32075894. doi:10.1212/WNL.0000000000009039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。